Xencor (XNCR) 10-Q2023 Q1 Quarterly report

Filed: 8 May 23, 5:15pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: aggregate, ascending, cevostamab, clearance, colorectal, COVID, deauthorized, diminished, disorder, escalation, EU, fixed, greater, heavily, individual, law, lingering, LLC, lower, mesothelin, microsatellite, mismatch, multivalent, mutated, NASDAQ, NMOSD, optica, ovarian, par, pembrolizumab, permitted, poster, pretreated, prevailing, prior, proficient, registration, repair, shelf, spectrum, stable, statement, strong, SVB, vitro, vivo

Removed: AChR, actively, administration, aggressive, agreed, alter, AMG, Amgen, amortize, apply, approximately, beneficial, biased, build, building, capitalize, case, chain, characterization, characterize, Code, collaborating, competitive, Corporation, decided, decreased, deducted, delayed, designing, direct, disrupt, dosing, duration, earlier, earn, efficacy, emergency, enacted, enrolled, enrollment, entitle, environmental, expression, favorable, federal, fifteen, FL, follicular, frequency, functionality, gastric, gastroesophageal, GSK, guidance, headquartered, health, high, implemented, incorporate, indirect, induction, initiate, Innovation, interruption, introduced, investigate, investigating, JJDC, Johnson, kill, located, merged, mitigate, mixed, modularity, newly, NHL, NK, offered, Omicron, Oncology, onsite, paid, pair, pancreatic, partner, partnered, partnership, percent, peripheral, pharmacodynamic, pharmacokinetic, postponed, predicting, preferentially, priced, projected, proliferation, promissory, promoted, PSA, recruiting, regimen, region, reimbursement, returned, safe, signal, slower, Society, stopped, subvariant, suited, supply, sustained, taxable, TCJA, temporarily, testing, transferred, treated, triple, type, uniquely, unregistered, valency, validation, variety, Xevudy

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated XNCR transcripts

XNCR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Bassil I. Dahiyat, President & Chief Executive Officer of Xencor, Inc. (the “Company”), and John J. Kuch, Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:

1.The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 8, 2023

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 8th day of May 2023.


/s/ BASSIL I. DAHIYAT						/s/ JOHN J. KUCH
Bassil I. Dahiyat						John J. Kuch
President & Chief Executive Officer						Chief Financial Officer
(Principal Executive Officer)						(Principal Financial Officer)

This certification accompanies the Periodic Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Xencor, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.